Equities Analysts Issue Forecasts for SLDB FY2026 Earnings

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Solid Biosciences to a loss of $1.60 per share from a loss of $1.63, while maintaining a Buy rating. The consensus forecast is a loss of $1.65 per share.
• Solid Biosciences reported a quarterly loss of $0.36 per share, beating analysts’ estimate of a $0.41 loss by $0.05.
• Analyst sentiment is broadly positive: 11 analysts rate the stock Buy and one Strong Buy, versus one Sell; the average price target is $20. Shares opened at $6.59.

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Research analysts at HC Wainwright upped their FY2026 earnings estimates for shares of Solid Biosciences in a report issued on Thursday, November 5th. HC Wainwright analyst A. He now anticipates that the company will post earnings per share of ($1.60) for the year, up from their prior forecast of ($1.63). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Solid Biosciences' current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Solid Biosciences' Q4 2026 earnings at ($0.37) EPS, Q1 2027 earnings at ($0.38) EPS, Q2 2027 earnings at ($0.39) EPS, Q3 2027 earnings at ($0.40) EPS, Q4 2027 earnings at ($0.39) EPS and FY2027 earnings at ($1.56) EPS.

SLDB has been the topic of several other research reports. Truist Financial upped their price target on Solid Biosciences from $16.00 to $20.00 and gave the company a "buy" rating in a research note on Friday, August 21st. Loop Capital set a $25.00 price objective on Solid Biosciences in a research report on Monday, September 14th. Weiss Ratings restated a "sell (d-)" rating on shares of Solid Biosciences in a report on Thursday, October 15th. Royal Bank Of Canada assumed coverage on shares of Solid Biosciences in a report on Wednesday, September 16th. They issued an "outperform" rating and a $18.00 price objective on the stock. Finally, Cantor Fitzgerald upped their target price on shares of Solid Biosciences from $16.00 to $26.00 and gave the company an "overweight" rating in a research report on Thursday, August 27th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, Solid Biosciences has an average rating of "Moderate Buy" and an average target price of $20.00.

Solid Biosciences Price Performance

SLDB stock opened at $6.59 on Monday. The business has a fifty day moving average of $7.48 and a two-hundred day moving average of $7.66. The stock has a market cap of $735.51 million, a price-to-earnings ratio of -3.68 and a beta of 2.65. Solid Biosciences has a 52-week low of $3.79 and a 52-week high of $11.45.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.36) EPS for the quarter, beating analysts' consensus estimates of ($0.41) by $0.05.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp purchased a new position in Solid Biosciences during the 2nd quarter worth $2,429,000. Dimensional Fund Advisors LP increased its stake in Solid Biosciences by 40.8% in the first quarter. Dimensional Fund Advisors LP now owns 956,135 shares of the company's stock valued at $6,877,000 after purchasing an additional 277,051 shares during the period. Redmile Group LLC increased its stake in Solid Biosciences by 8.1% in the first quarter. Redmile Group LLC now owns 2,011,895 shares of the company's stock valued at $14,486,000 after purchasing an additional 151,353 shares during the period. Stempoint Capital LP purchased a new stake in shares of Solid Biosciences in the first quarter valued at about $1,407,000. Finally, Janus Henderson Group PLC purchased a new stake in shares of Solid Biosciences in the first quarter valued at about $28,877,000. Institutional investors and hedge funds own 81.46% of the company's stock.

About Solid Biosciences

Solid Biosciences Inc NASDAQ: SLDB is a biotechnology company focused on developing gene therapies for neuromuscular and other serious genetic diseases. The company uses adeno-associated virus (AAV) delivery technologies and genetic medicine approaches to develop treatments intended to address the underlying causes of disease.

Its lead investigational program, SGT-003, is being developed as a gene therapy for Duchenne muscular dystrophy, a severe X-linked muscle-wasting disorder. Solid Biosciences also has additional preclinical and clinical programs targeting other neuromuscular conditions, including diseases associated with defects in muscle proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.